Liver disease

A review concluded moderate coffee/caffeine intake correlates with lower risk and slower progression of chronic liver diseases including NASH, cirrhosis, and hepatocellular carcinoma via anti-fibrotic and anti-inflammatory mechanisms.

Effect

Benefit

Population

Patients with liver disease

A pharmacology review summarized preclinical and clinical evidence that caffeine, mainly as an adenosine receptor antagonist, may help prevent and treat various liver diseases when consumed in moderate coffee amounts.

Effect

Benefit

Dose

35 mg/day

In rats with thioacetamide-induced liver injury, co-treatment with caffeine reduced oxidative stress, inflammation, and fibrosis markers and restored histology, suggesting anti-fibrogenic and anti-inflammatory hepatic effects.

Dose

37.5 mg/kg

Population

Adults

In rats, caffeine co-administration during thioacetamide exposure blocked TGF-β elevation and reduced fibrosis, collagen, and inflammatory markers, preventing experimental cirrhosis over 8 weeks.

Duration

8 weeks

A review concluded SAMe has evidence for depression, osteoarthritis, and liver disease, though indication-specific trial quality varies.

In an observational study of 80 participants, for 48 weeks, prospective studies are still needed, however, to validate the role of vitamin K1 in the chronic liver failure.

Effect

Benefit

Duration

48 weeks

Population

Men

Participants

80

In an RCT of 237 participants, 50 mg α-tocopherol + 20 mg β-carotene/day, supplemental α-tocopherol, β-carotene, or both, relative to placebo, did not reduce the risk of liver cancer or CLD, either overall, during the intervention or during the post-intervention period.

Effect

No Benefit

Dose

50 mg α-tocopherol + 20 mg β-carotene/day

Population

Liver disease patients

Participants

237

Ages

5–8